All Online

1 - 12 of 27 results

Refine

Active filters

Diabetes Mellitus, Type 2
1.25 CME CREDITS

This activity is part of the ConnectED Learning: Diabetes curriculum. It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic live educational program will feature renowned faculty experts who will lead an interactive discussion on important evidence supporting emerging clinical strategies, shared decision making, and ways in which to individualize care to best manage the complex challenges of diabetes and the progression of disease. It will include therapeutic approaches that can reduce the risks such as hypoglycemia, weight gain, and cardiovascular events.


1 CME CREDIT

This activity is part of the ConnectED Learning: Diabetes curriculum. Join expert faculty as they address your remaining questions and provide a distillation of clinical pearls from the ConnectED Learning Curriculum on the management of diabetes


0.56 CME CREDIT

This activity is part of the ConnectED Learning: Diabetes curriculum. In this Expert Perspective, Dr. Richard Pratley outlines the main facets of utilizing oral combination therapy to intensify treatment in order to achieve HbA1c goals while minimizing side effects and cardiovascular risk.


0.57 CME CREDIT

This activity is part of the ConnectED Learning: Diabetes curriculum. This case will highlight best practices of intensifying therapy with oral combination regimens in individuals with T2DM.


0.75 CME CREDIT

This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.


1 CME CREDIT

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin analogs are essential antihyperglycemic therapies for many patients with type 2 diabetes mellitus (T2DM) (eg, those in need of large glucose-lowering effects or, based on recent updates to the official indications for 2 of the GLP-1 RAs). This Engaging the Patient activity will discuss newer insulin therapies as well as GLP-1 injectable therapies, including rationales and clinical trial evidence for combining these two agents. The activity includes a demonstration of clinician and patient interactions-ways to educate patients on the use of injectable medications, as well as approaches to reducing hypoglycemia and improving patient adherence.


0.57 CME CREDIT

This case outlines nuances of intensifying therapy with oral antidiabetic agents based on patient and disease characteristics


0.78 CME CREDIT

Follow the complex case of a 55-year-old patient who presents with long-standing, uncontrolled type 2 diabetes requiring individualized care. Filled with common scenarios relevant to primary care, this case distinguishes nuances in management based on patient- and disease-specific factors while enhancing your knowledge on the myriad diabetes therapies available today.


1 CME CREDIT

Selecting the right therapy and knowing when it is time to intensify treatment for patients with type 2 diabetes is critical, but the availability of numerous antihyperglycemic agents can cause confusion for the clinician. This program examines the role of various type 2 diabetes therapies in the treatment paradigm and how effective patient communication strategies help to achieve glycemic goals and slow disease progression.


0.75 CME CREDIT

In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).


1.5 CME CREDITS

It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic and interactive live educational program will feature renowned faculty experts who will lead an interactive discussion of important evidence supporting the use of individualized oral combination therapy to attain glycemic control while minimizing weight gain, as well as hypoglycemic and CV risk.